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(ASP) aim for de-escalation of initial
broad-spectrum antibiotics to reduce
selective pressure, toxicity, and costs.
The literature on antimicrobial de-
escalation in septic cancer patients is
scarce. We retrospectively examined
the frequency and outcomes of
antimicrobial de-escalation in 105
adult cancer patients admitted to a
20-bed intensive care unit (ICU) with
severe sepsis from the Urgent Care
Center (UCC) at Memorial Sloan
Kettering Cancer Center, New York,
NY between January 2008 and March
2013 (eSupplement Fig. 1). The hos-
pital has an active ASP that
developed local sepsis guidelines
with the UCC and ICU. De-escalation
was defined as discontinuing or nar-
rowing of the regimen by ICU day 5
[1]. Primary outcomes were length of
stay (LOS) (ICU, hospital) and all-
cause mortality (ICU, hospital,
28-day).
Nearly all study patients (96 %)
were on empiric combination therapy
on ICU admission; 61 (58 %) of 105
patients had therapy de-escalated.
The mean number of antibiotics per
patient was 3 ± 0.8 in both groups on
ICU admission. By ICU day 5, the
mean number of antibiotics remained
at 3 ± 0.9 in the non de-escalation
group, while the mean number of
antibiotics dropped to 1.5 ± 0.8 in
the de-escalation group. While the
average duration of antibiotic therapy
was the same for both groups
(Table 1), durations of certain
antibiotics (e.g., resistant gram-posi-
tive agents, anti-pseudomonal beta-
lactams, quinolones, metronidazole)
were significantly shorter for de-
escalated patients (eSupplement
Table 1). Initial therapy was appro-
priate in 58 (97 %) of 60
microbiologically confirmed infec-
tions (eSupplement Table 2).
The de-escalation group had a
lower mean lactate on ICU admission
(2.4 ± 2.1 vs 3.2 ± 2.3 mmol/L,
P = 0.03), a lower mean SOFA score
on ICU day 5 (5.1 ± 3.9 vs 7 ± 3.5,
P = 0.002), less history of resistant
organisms (3 vs 16 %, P = 0.03), and
fewer concomitant multiple infections
(16 vs 36 %, P = 0.02) compared to
the non de-escalation group. There
were no differences in ICU, hospital,
or 28-day mortality between the two
groups (Table 1). The de-escalation
group had shorter ICU (8.1 vs
11.2 days, P = 0.006) and hospital
(17.1 vs 23.4 days, P = 0.04) LOS
after adjusting for known prognostic
factors in a multivariate analysis
(eSupplement Table 3).
Our frequency of de-escalation
(58 %) was higher than that of
Mokart et al. (44 %), the only other
de-escalation study in septic cancer
patients [2]. The dissimilarities in
study populations may account for the
difference in de-escalation rates
between our two cancer centers.
In our study, by ICU day 5, the non
de-escalation group had a higher
mean SOFA score compared to the
de-escalated patients, implying
slower clinical resolution. One factor
that may be influencing the decision
to de-escalate is the physician’s per-
ception of the clinical progress of the
septic patient, and following serial
SOFA scores, or other severity-of-
illness measures as suggested by
Joung et al. [3], may be useful to de-
escalate patients safely.
In conclusion, de-escalating
antimicrobial therapy in septic cancer
patients admitted to the ICU from the
UCC was associated with shorter ICU
and hospital LOS. No adverse effect
of de-escalation on mortality was
found. Future sepsis studies should
focus on investigating whether de-
escalation can definitively improve
patient outcomes and/or slow emerg-
ing antimicrobial resistance.
Compliance with ethical standards
Conflicts of interest None of the authors
have any financial disclosures or conflicts of
interest.
Intensive Care Med (2015) 41:2022–2023
DOI 10.1007/s00134-015-4016-6 LETTER
Open Access This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 Interna-
tional License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and
reproduction in any medium, provided you
give appropriate credit to the original
author(s) and the source, provide a link to
the Creative Commons license, and indicate
if changes were made.
References
1. Weiss E, Zahar JR, Lesprit P, Ruppe E,
Leone M, Chastre J, Lucet JC, Paugam-
Burtz C, Brun-Buisson C, Timsit JF, De-
escalation Study Group (2015)
Elaboration of a consensual definition of
de-escalation allowing a ranking of beta-
lactams. Clin Microbiol Infect
21:649.e1–649.e10. doi:
10.1016/j.cmi.2015.03.013
2. Mokart D, Slehofer G, Lambert J,
Sannini A, Chow-Chine L, Brun JP,
Berger P, Duran S, Faucher M, Blache
JL, Saillard C, Vey N, Leone M (2014)
De-escalation of antimicrobial treatment
in neutropenic patients with severe
sepsis: results from an observational
study. Intensive Care Med 40:41–49
3. Joung MK, Lee JA, Moon SY, Cheong
HS, Joo EJ, Ha YE, Sohn KM, Chung
SM, Suh GY, Chung DR, Song JH, Peck
KR (2011) Impact of de-escalation
therapy on clinical outcomes for
intensive care unit-acquired pneumonia.
Crit Care 15:R79. doi:10.1186/cc10072
A. Paskovaty ())
Department of Pharmacy, Memorial Sloan
Kettering Cancer Center, 1275 York
Avenue, New York, NY 10065, USA
e-mail: paskovaa@mskcc.org
Tel.: 212-639-7212
S. M. Pastores  N. Kostelecky
Critical Care Medicine Service, Department
of Anesthesiology and Critical Care
Medicine, Memorial Sloan Kettering
Cancer Center, New York, NY 10065, USA
E. R. Riedel
Department of Epidemiology and
Biostatistics, Memorial Sloan Kettering
Cancer Center, New York, NY 10065, USA
Z. Gedrimaite  S. K. Seo
Infectious Disease Service, Department of
Medicine, Memorial Sloan Kettering
Cancer Center, New York, NY 10065, USA






Age (years) 62.5 (±13.2) 61.7 (±12.8) 0.7
Gender (male) 39 (64 %) 28 (64 %) 1
Cancer type
Hematologic 24 (39 %) 17 (39 %) 1
Solid 37 (61 %) 27 (61 %)
Neutropenia on ICU admission 13 (21 %) 11 (26 %) 0.64
History of antibiotic allergy 15 (25 %) 8 (18 %) 0.48
Prior history of resistant organism 2 (3 %) 7 (16 %) 0.03
Lactate level (mmol/L) on ICU admission 2.4 (±2.1) 3.2 (±2.3) 0.03
Blood culture on ICU admission that turned positive 15 (25 %) 7 (16 %) 0.34
Time to first antibiotic administration
from initial blood culture collection (hours)
1.1 (±3) 1 (±3) 0.86
Concomitant multiple infections 10 (16 %) 16 (36 %) 0.02
Use of MV during ICU stay 29 (48 %) 22 (50 %) 0.84
Use of MV on day 5 20 (33 %) 18 (41 %) 0.42
Total MV duration (days) (for those on MV) 7.1 (±3.4) 10.1 (±6.6) 0.18
Use of VP during ICU stay 42 (69 %) 35 (80 %) 0.27
MPM II score on ICU admission 0.5 (±0.2) 0.5 (±0.3) 0.96
SOFA score on ICU admission 7.2 (±3.3) 8 (±3.4) 0.18
SOFA score on ICU day 5 5.1 (±3.9) 7 (±3.5) 0.002
Difference between SOFA
on day 5 and SOFA on ICU admission
-2.1 (±3.5) -1 (±3.5) 0.05
Duration of therapy 13.3 (±7.2) 15.5 (±11.1) 0.6
ICU mortality 11 (18 %) 10 (23 %) 0.62
Hospital mortality 21 (34 %) 15 (34 %) 1
28-day mortality 24 (39 %) 15 (34 %) 0.68
ICU LOS 8.1 (±4.6) 11.2 (±7.4) 0.001
Hospital LOS 17.1 (±22.9) 23.4 (±17.6) 0.005
Data are expressed as number (percentage) or mean (±standard
deviation). P\ 0.05 was considered significant
ICU intensive care unit, LOS length of stay, MV mechanical ven-
tilation, MPM mortality probability model, SOFA sequential organ
failure assessment, VP vasopressors
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